HRP20150778T1 - Derivati hidroksamske kiseline - Google Patents
Derivati hidroksamske kiseline Download PDFInfo
- Publication number
- HRP20150778T1 HRP20150778T1 HRP20150778TT HRP20150778T HRP20150778T1 HR P20150778 T1 HRP20150778 T1 HR P20150778T1 HR P20150778T T HRP20150778T T HR P20150778TT HR P20150778 T HRP20150778 T HR P20150778T HR P20150778 T1 HRP20150778 T1 HR P20150778T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- compound
- image
- salt
- disease
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000026305 Myelodysplastic-Myeloproliferative disease Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 229940097042 glucuronate Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0013—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (7)
1. Spoj Formule I, ili neka njegova farmaceutski prihvatljiva sol:
[image]
naznačen time, što je Z odsutno; m je 5, 6, 7 ili 8; P predstavlja
[image]
a
X1 i X2, svaki nezavisno, predstavlja halo ili OSO2RC, gdje RC predstavlja alkil, alkenil ili alkinil.
2. Spoj ili sol prema Zahtjevu 1, naznačen time, što taj spoj predstavlja
[image]
[image]
ili
[image]
3. Spoj ili sol prema Zahtjevu 2, koji predstavlja
[image]
4. Spoj prema bilo kojem od prethodnih Zahtjeva 1 do 3, naznačen time, što spomenuta sol predstavlja klorid, bromid, jodid, sulfat, bisulfat, sulfamat, nitrat, fosfat, citrat, metansulfonat, trifluoroacetat, glutamat, glukuronat, glutarat, malat, maleat, sukcinat, fumarat, tartrat, tozilat, salicilat, laktat, naftalinesulfonat ili acetat.
5. Farmaceutska kompozicija, koja sadrži neki od spojeva prema Zahtjevima 1 do 4, i neki farmaceutski prihvatljiv nosač.
6. Uporaba spoja ili soli, prema bilo kojem od Zahtjeva 1 do 4, ili neke kompozicije, prema Zahtjevu 5, u tretiranju neke neoplastične bolesti ili neke imuno bolesti.
7. Spoj, sol ili kompozicija, prema Zahtjevu 6, naznačeni time, što se spomenuta neoplastična bolest bira između slijedećih: kancer pluća, kancer glave i vrata, kancer središnjeg živčanog sustava, kancer prostate, kancer testisa, kolorektalni kancer, kancer pankreasa, kancer jetre, kancer želuca, kancer žučnog trakta, kancer jednjaka, gastrointestijalni stromalni tumor, kancer dojke, kancer cerviksa, kancer jajnika, kancer uterusa, leukemija, limfomi, multipli mijelom, melanom, karcinom bazalnih stanica, karcinom skvamoznih stanica, kancer mjehura, kancer bubrega, sarkom, mezotelioma, timom, mijelodisplastični sindrom i mijeloproliferativna bolest.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14700209P | 2009-01-23 | 2009-01-23 | |
| US15649609P | 2009-02-28 | 2009-02-28 | |
| US25215609P | 2009-10-15 | 2009-10-15 | |
| US25265209P | 2009-10-17 | 2009-10-17 | |
| EP20100733747 EP2389375B1 (en) | 2009-01-23 | 2010-01-07 | Hydroxamic acid derivatives |
| PCT/US2010/020373 WO2010085377A2 (en) | 2009-01-23 | 2010-01-07 | Hydroxamic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150778T1 true HRP20150778T1 (hr) | 2015-08-28 |
Family
ID=42356377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150778TT HRP20150778T1 (hr) | 2009-01-23 | 2015-07-15 | Derivati hidroksamske kiseline |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8609864B2 (hr) |
| EP (1) | EP2389375B1 (hr) |
| JP (1) | JP5576402B2 (hr) |
| CN (1) | CN102186842B (hr) |
| CA (1) | CA2750413C (hr) |
| CY (1) | CY1116602T1 (hr) |
| DK (1) | DK2389375T3 (hr) |
| ES (1) | ES2544803T3 (hr) |
| HR (1) | HRP20150778T1 (hr) |
| HU (1) | HUE025349T2 (hr) |
| ME (1) | ME02254B (hr) |
| PL (1) | PL2389375T3 (hr) |
| PT (1) | PT2389375E (hr) |
| RS (1) | RS54192B1 (hr) |
| SI (1) | SI2389375T1 (hr) |
| SM (1) | SMT201500196B (hr) |
| WO (1) | WO2010085377A2 (hr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9174970B2 (en) | 2008-01-22 | 2015-11-03 | Dow Agrosciences Llc | 5-fluoro pyrimidine derivatives |
| CA2750413C (en) * | 2009-01-23 | 2016-06-21 | Northlake Biosciences Llc | Hydroxamic acid derivatives |
| UA106889C2 (uk) | 2009-08-07 | 2014-10-27 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Похідні n1-ацил-5-фторпіримідинону |
| CA2769073C (en) | 2009-08-07 | 2018-07-24 | Dow Agrosciences Llc | N1-sulfonyl-5-fluoropyrimidinone derivatives |
| UA112284C2 (uk) | 2009-08-07 | 2016-08-25 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Похідні 5-фторпіримідинону |
| UA107671C2 (en) * | 2009-08-07 | 2015-02-10 | Dow Agrosciences Llc | N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives |
| CN102791135B (zh) | 2010-01-07 | 2015-05-20 | 陶氏益农公司 | 噻唑并[5,4-d]嘧啶以及它们作为农用化学品的用途 |
| CN101928234B (zh) * | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法 |
| WO2011113175A1 (zh) * | 2010-03-15 | 2011-09-22 | Gao Feng | 阿糖胞苷前药衍生物及其在抗癌抗肿瘤中的用途 |
| US8980909B2 (en) * | 2011-01-12 | 2015-03-17 | Crystal Biopharmaceutical Llc | HDAC inhibiting derivatives of camptothecin |
| JP6128658B2 (ja) | 2011-08-17 | 2017-05-17 | アダマ・マクテシム・リミテッド | ５−フルオロ−４−イミノ−３−（置換）−３，４−ジヒドロピリミジン−２−（１ｈ）−オン誘導体 |
| CN102993102B (zh) * | 2011-09-16 | 2016-08-24 | 杭州民生药业有限公司 | [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法 |
| ME03088B (me) * | 2011-09-18 | 2019-01-20 | Euro Celtique Sa | Postupak za proizvodnju stabilnog, injektabilnog rastvora noradrenalina niske koncentracije |
| CN102432654A (zh) * | 2011-09-26 | 2012-05-02 | 宋云龙 | 吉西他滨酰胺衍生物及其制备方法和用途 |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| CN102584737A (zh) * | 2012-02-07 | 2012-07-18 | 盛世泰科生物医药技术(苏州)有限公司 | 抑制组蛋白去乙酰酶的物质的组成和使用 |
| EP2725029A1 (en) * | 2012-10-29 | 2014-04-30 | Laboratoire Biodim | New antibacterial compounds and biological applications thereof |
| CN104994859B (zh) | 2012-12-28 | 2018-10-26 | 阿达玛马克西姆股份有限公司 | 1-(取代的苯甲酰基)-5-氟-4-亚氨基-3-甲基-3,4-二氢嘧啶-2(1h)-酮衍生物 |
| MX2015008441A (es) | 2012-12-28 | 2015-09-23 | Dow Agrosciences Llc | Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3, 4-dihidropirimidin-1 (2h)-carboxilato. |
| RU2015131149A (ru) | 2012-12-28 | 2017-02-03 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | N-(замещенные)-5-фтор-4-имино-3-метил-2-оксо-3,4-дигидропиримидин-1(2н)-карбоксамидные производные |
| MX2015008565A (es) | 2012-12-31 | 2015-09-07 | Dow Agrosciences Llc | Derivados de 3-alquil-5-fluoro-4-sustituido-imino-3,4-dihidropirim idin-2(1h)-ona como fungicidas. |
| CN103340845B (zh) * | 2013-06-26 | 2015-03-18 | 浙江省食品药品检验研究院 | 药物组合物 |
| JP6212831B2 (ja) * | 2013-12-04 | 2017-10-18 | 杭州源昶医薬科技有限公司 | ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途 |
| UA124962C2 (uk) | 2013-12-31 | 2021-12-22 | Адама Махтешім Лтд. | Синергічні фунгіцидні суміші та композиції для контролю грибків |
| WO2015103142A1 (en) | 2013-12-31 | 2015-07-09 | Dow Agrosciences Llc | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1- (arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation |
| WO2015117116A1 (en) | 2014-02-03 | 2015-08-06 | Halliburton Energy Services, Inc. | Optimizing a grid for finite element solutions for subterranean region simulations |
| GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| MX2017005158A (es) * | 2014-10-28 | 2017-07-27 | Shionogi & Co | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). |
| PT3297992T (pt) | 2015-05-22 | 2020-03-17 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de alquilo heterocíclicos como inibidores seletivos da histona desacetilase e composições farmacêuticas que compreendem os mesmos |
| EP3347099B1 (en) * | 2015-09-10 | 2023-10-25 | Becton, Dickinson and Company | Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide |
| AU2016426574B2 (en) * | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| CN106905191B (zh) * | 2017-03-05 | 2019-03-29 | 北京化工大学 | 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途 |
| CN106883217B (zh) * | 2017-04-01 | 2020-05-22 | 清华大学深圳研究生院 | 一种核苷碱基异羟肟酸衍生化合物及其制备方法与应用 |
| GB201709405D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| CA3071345A1 (en) * | 2017-07-28 | 2019-01-31 | Yale University | Anticancer drugs and methods of making and using same |
| US11199529B2 (en) | 2017-09-21 | 2021-12-14 | Becton, Dickinson And Company | Hazardous contaminant collection kit and rapid testing |
| CN108299313B (zh) * | 2018-01-16 | 2020-10-02 | 长沙霍滋生物科技有限公司 | 一种化合物及其在药学上的应用 |
| CN109516957A (zh) * | 2018-08-03 | 2019-03-26 | 杭州梯诺医药科技有限公司 | Nl-101多晶型及其制备方法 |
| WO2020026054A1 (en) * | 2018-08-03 | 2020-02-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of cancer |
| CA3110611A1 (en) * | 2018-09-01 | 2020-03-05 | Beijing Showby Pharmaceutical Co., Ltd. | Phosphate of platinum compound and preparation method therefor |
| AU2019402158A1 (en) * | 2018-12-18 | 2021-06-10 | Mundipharma International Corporation Limited | Compounds for treating lymphoma or a T-cell malignant disease |
| CN212748381U (zh) | 2019-01-28 | 2021-03-19 | 贝克顿·迪金森公司 | 一种有害污染物检测系统和一种有害污染物收集装置 |
| CN112209884B (zh) * | 2019-07-12 | 2022-11-11 | 杭州梯诺医药科技有限公司 | 1-h苯并咪唑衍生物、制备方法及其应用 |
| CN113307829B (zh) * | 2021-05-08 | 2022-05-24 | 苏州科技大学 | 一种以异羟肟酸衍生物为配体的铂(ii)配合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| EP1598067B1 (en) | 2000-09-29 | 2009-05-06 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage for the treatment of malaria |
| JP4993374B2 (ja) * | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| GB0621160D0 (en) * | 2006-10-24 | 2006-12-06 | Imp College Innovations Ltd | Compounds and uses thereof |
| WO2009100045A1 (en) | 2008-02-04 | 2009-08-13 | Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| CA2750413C (en) * | 2009-01-23 | 2016-06-21 | Northlake Biosciences Llc | Hydroxamic acid derivatives |
-
2010
- 2010-01-07 CA CA2750413A patent/CA2750413C/en active Active
- 2010-01-07 PT PT107337479T patent/PT2389375E/pt unknown
- 2010-01-07 ME MEP-2015-541A patent/ME02254B/me unknown
- 2010-01-07 CN CN201080002890.XA patent/CN102186842B/zh active Active
- 2010-01-07 WO PCT/US2010/020373 patent/WO2010085377A2/en active Application Filing
- 2010-01-07 ES ES10733747.9T patent/ES2544803T3/es active Active
- 2010-01-07 EP EP20100733747 patent/EP2389375B1/en active Active
- 2010-01-07 PL PL10733747T patent/PL2389375T3/pl unknown
- 2010-01-07 DK DK10733747.9T patent/DK2389375T3/en active
- 2010-01-07 RS RS20150541A patent/RS54192B1/en unknown
- 2010-01-07 US US13/143,155 patent/US8609864B2/en not_active Ceased
- 2010-01-07 SI SI201030986T patent/SI2389375T1/sl unknown
- 2010-01-07 HU HUE10733747A patent/HUE025349T2/en unknown
- 2010-01-07 JP JP2011547997A patent/JP5576402B2/ja active Active
- 2010-01-07 US US14/972,750 patent/USRE46144E1/en active Active
-
2013
- 2013-11-08 US US14/075,145 patent/US9096627B2/en active Active
-
2015
- 2015-07-15 HR HRP20150778TT patent/HRP20150778T1/hr unknown
- 2015-08-13 SM SM201500196T patent/SMT201500196B/xx unknown
- 2015-08-13 CY CY20151100709T patent/CY1116602T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2750413A1 (en) | 2010-07-29 |
| WO2010085377A3 (en) | 2011-03-31 |
| SMT201500196B (it) | 2015-10-30 |
| PL2389375T3 (pl) | 2015-11-30 |
| JP5576402B2 (ja) | 2014-08-20 |
| ME02254B (me) | 2015-12-31 |
| USRE46144E1 (en) | 2016-09-13 |
| SI2389375T1 (sl) | 2015-11-30 |
| DK2389375T3 (en) | 2015-08-24 |
| HUE025349T2 (en) | 2016-02-29 |
| EP2389375A4 (en) | 2012-09-19 |
| CN102186842B (zh) | 2014-07-23 |
| US9096627B2 (en) | 2015-08-04 |
| US20110269706A1 (en) | 2011-11-03 |
| CY1116602T1 (el) | 2018-03-07 |
| US8609864B2 (en) | 2013-12-17 |
| EP2389375A2 (en) | 2011-11-30 |
| CA2750413C (en) | 2016-06-21 |
| ES2544803T3 (es) | 2015-09-04 |
| CN102186842A (zh) | 2011-09-14 |
| JP2012515776A (ja) | 2012-07-12 |
| WO2010085377A2 (en) | 2010-07-29 |
| RS54192B1 (en) | 2015-12-31 |
| EP2389375B1 (en) | 2015-05-20 |
| US20140066419A1 (en) | 2014-03-06 |
| PT2389375E (pt) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150778T1 (hr) | Derivati hidroksamske kiseline | |
| JP2014502638A5 (hr) | ||
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| FI3328827T3 (fi) | Glutamiinianalogien aihiolääkkeitä | |
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| JP2010001302A5 (hr) | ||
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| HRP20171727T1 (hr) | Novi terapeutici | |
| JP2009514870A5 (hr) | ||
| JP2013523756A5 (hr) | ||
| JP2017510661A5 (hr) | ||
| SI2758052T1 (en) | A pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide | |
| JP2017509586A5 (hr) | ||
| NZ600887A (en) | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts | |
| HRP20161522T1 (hr) | Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom | |
| JP2017519027A5 (hr) | ||
| JP2017518291A5 (hr) | ||
| NZ626942A (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JP2017505782A5 (hr) | ||
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| JP2014527042A5 (hr) | ||
| JP2017537969A5 (hr) | ||
| JP2014509653A5 (hr) | ||
| JP2015505542A5 (hr) |